Contest Catch the Monkey 12.06.2021
Vassago1 scored a decisive win in our stockpicking contest Catch the Monkey 12.06.2021 ahead of skyrockerZoe with a performance of 37.298%. KongVestor had a hard time, his performance of 7.396% was only enough for position 13 on the leaderboard.
We discuss all securities, matching the rule For 5 securities, where you also told the community the pros and cons you get 1% extra performance
The most often selected stocks in this stockpicking contest were AMC Entertainment Holdings Inc., Tesla Inc and Bitcoin. AMC Entertainment Holdings Inc. was selected 10 times, Tesla Inc was picked 8 times and Bitcoin 8 times. The best predictions were Buy Washington Prime Group Inc. by Global_Player, Buy AMC Entertainment Holdings Inc. by AlexKlar and Buy 1847 Goedeker Inc. by skyrockerZoe. Buy Washington Prime Group Inc. had a performance of 212.849%, followed by Buy AMC Entertainment Holdings Inc. with 77.158%, and Buy 1847 Goedeker Inc. managed to achieve a performance of 65.161%.
| Name | Prediction | Start price | Perf. (%) |
|---|---|---|---|
| American Superconductor Corp | buy | €14.10 | -10.638% |
| SemiLEDs Corp. | buy | €17.00 | 5.882% |
| Performant Financial | buy | €3.98 | -19.598% |
| Bank of the Ozarks Inc. | buy | €36.20 | -0.553% |
| PERASO Inc. | buy | €6.90 | -15.217% |
| Name | Prediction | Start price | Perf. (%) |
|---|---|---|---|
| EOS | buy | €5.08 | -18.475% |
| Cosmos | buy | €10.53 | -6.343% |
| Polkadot [IOU] | buy | €17.02 | 2.655% |
| Ethereum Classic | buy | €54.33 | -12.343% |
| Dash | buy | €152.81 | -8.272% |
| Name | Prediction | Start price | Perf. (%) |
|---|---|---|---|
| Ethereum Classic | buy | €56.28 | -15.377% |
| Polkadot [IOU] | buy | €17.78 | -1.523% |
| Bitcoin Cash | buy | €574.06 | -15.517% |
| EOS | buy | €5.32 | -21.990% |
| Waves | buy | €11.43 | 4.325% |
| Name | Prediction | Start price | Perf. (%) |
|---|---|---|---|
| EOS | buy | €4.81 | -13.818% |
| Ethereum Classic | buy | €52.70 | -9.624% |
| Bitcoin Cash / BCC | buy | €542.19 | -10.981% |
| Monero | buy | €226.56 | -8.504% |
| Bitcoin Cash | buy | €542.38 | -10.582% |
| Name | Prediction | Start price | Perf. (%) |
|---|---|---|---|
| 1847 Goedeker Inc. | sell | €1.55 | 65.161% |
| Moxian Inc. | sell | €9.65 | 32.643% |
| Celtic | sell | €1.15 | 15.652% |
| Everarc Holdings Ltd. | sell | €6.05 | 0.000% |
| Provention Bio Inc | sell | €6.30 | -0.794% |
| Name | Prediction | Start price | Perf. (%) |
|---|---|---|---|
| Delivery Hero SE | sell | €111.10 | 0.090% |
| Getinge AB B | buy | €28.89 | 6.231% |
| Exact Sciences | buy | €91.24 | 10.368% |
| CENIT AG | buy | €14.00 | 0.714% |
| Name | Prediction | Start price | Perf. (%) |
|---|---|---|---|
| AMC Entertainment Holdings Inc. | buy | €40.64 | 0.296% |
| Twitter Inc. | buy | €47.71 | 4.716% |
| Gilead Sciences Inc | sell | €55.46 | 2.398% |
| Name | Prediction | Start price | Perf. (%) |
|---|---|---|---|
| Meta Platforms Inc. | sell | €269.25 | 1.597% |
| Biofrontera AG | buy | €2.88 | -1.389% |
Top Performer
| Prediction | Security | User | Perf. (%) |
|---|---|---|---|
| B | Washington Prime Group Inc. | Global_Player | 212.849% |
| B | AMC Entertainment Holdings Inc. | AlexKlar | 77.158% |
| B | 1847 Goedeker Inc. | skyrockerZoe | 65.161% |
| B | 1847 Goedeker Inc. | quelbe60 | 65.161% |
| B | The9 Ltd ADR | quelbe60 | 64.103% |
| Prediction | Security | User | Perf. (%) |
|---|---|---|---|
| S | windeln.de SE | Ilyo | -48.936% |
| S | windeln.de SE | tbackenh | -32.235% |
| S | Bank of Ayudhya -fgn- | nvestor | -29.091% |
| S | Horizen | blaugold | -28.559% |
| S | Zcash | blaugold | -27.445% |
Comments
Meine aducanumab-Wette ist gut aufgegangen, dass war der Grundstein des Erfolgs. 📈
Sie sehen sie nur als Beobachtungsaktie
- Ende April gab Adverum bekannt, dass seine experimentelle Gentherapie für diabetisches Makulaödem (DME), bekannt als ADVM-022, in seiner laufenden Mid-Stage-Studie auf einen ernsthaften Haken gestoßen ist. Insbesondere soll ein Patient in der Studie Hypotonie (niedriger Augeninnendruck) und Sehverlust im behandelten Auge entwickelt haben, was das Unternehmen dazu zwang, sein klinisches Programm für ADVM-022 zu überdenken.
- Als direkte Folge dieses unerwarteten klinischen Rückschlags veröffentlichte Sonic Fund II, ein Hauptaktionär des Unternehmens, eine vernichtende Pressemitteilung, in der die Ernennung von drei neuen Vorstandsmitgliedern zur Überwachung der klinischen Entwicklung von ADVM-022 gefordert wurde.